Clinical Trials Browser

Completed × Neoplasms × spartalizumab × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04669899 2024-04-09

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Phase 1/2 Completed

190 enrolled

Tumor-Agnostic

Neoplasms

NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Phase 1/2 Completed

40 enrolled

Gynecologic

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT02828098 2024-01-29

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Phase 1 Completed

44 enrolled

Tumor-Agnostic

Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

283 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Clinical Trials

IT-01

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)